Sumitomo Mitsui Trust Holdings Inc. Sells 41,733 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Sumitomo Mitsui Trust Holdings Inc. lessened its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,478,562 shares of the company’s stock after selling 41,733 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned about 3.88% of Intellia Therapeutics worth $106,061,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of NTLA. MetLife Investment Management LLC boosted its position in shares of Intellia Therapeutics by 54.7% during the 1st quarter. MetLife Investment Management LLC now owns 37,362 shares of the company’s stock valued at $2,715,000 after acquiring an additional 13,209 shares during the last quarter. Rhumbline Advisers lifted its position in Intellia Therapeutics by 2.7% in the 1st quarter. Rhumbline Advisers now owns 98,247 shares of the company’s stock worth $7,140,000 after buying an additional 2,620 shares during the last quarter. Cibc World Market Inc. lifted its position in Intellia Therapeutics by 47.3% in the 1st quarter. Cibc World Market Inc. now owns 4,740 shares of the company’s stock worth $344,000 after buying an additional 1,522 shares during the last quarter. Blair William & Co. IL lifted its position in Intellia Therapeutics by 11.9% in the 1st quarter. Blair William & Co. IL now owns 10,362 shares of the company’s stock worth $753,000 after buying an additional 1,100 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in Intellia Therapeutics in the 1st quarter worth approximately $307,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

NTLA opened at $21.81 on Wednesday. Intellia Therapeutics, Inc. has a 52-week low of $21.80 and a 52-week high of $47.48. The stock’s 50 day moving average price is $27.65 and its 200-day moving average price is $28.08.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.01. The company had revenue of ($1.92) million for the quarter, compared to analysts’ expectations of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same period in the prior year, the firm earned ($1.40) earnings per share. As a group, sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP James Basta sold 2,297 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the sale, the executive vice president now directly owns 81,571 shares of the company’s stock, valued at $2,691,027.29. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.00% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Canaccord Genuity Group boosted their target price on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. The Goldman Sachs Group downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $136.00 to $32.00 in a research report on Friday, February 23rd. Wolfe Research began coverage on Intellia Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Finally, Wedbush reiterated a “neutral” rating and issued a $29.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.